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Novel Neuroprotective GSK-3 Inhibitor Restricts Tat-Mediated HIV-
1 Replication
Irene Guendel,a Sergey Iordanskiy,a Rachel Van Duyne,a,b Kylene Kehn-Hall,a Mohammed Saifuddin,a Ravi Das,a Elizabeth Jaworski,a
Gavin C. Sampey,a Svetlana Senina,a Leonard Shultz,c Aarthi Narayanan,a Hao Chen,d Benjamin Lepene,f Chen Zeng,d,e
Fatah Kashanchia
‹National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, Virginia, USAa; Department of Microbiology, Immunology and Tropical
Medicine, George Washington University School of Medicine, Washington, DC, USAb; Jackson Laboratory, Bar Harbor, Maine, USAc; Department of Physics, George
Washington University, Washington, DC, USAd; Department of Physics, Huazhong University of Science and Technology, Wuhan, Chinae; Ceres Nanosciences, Inc.,
Manassas, Virginia, USAf
The implementation of new antiretroviral therapies targeting transcription of early viral proteins in postintegrated HIV-1 can
aid in overcoming current therapy limitations. Using high-throughput screening assays, we have previously described a novel
Tat-dependent HIV-1 transcriptional inhibitor named 6-bromoindirubin-3=-oxime (6BIO). The screening of 6BIO derivatives
yielded unique compounds that show potent inhibition of HIV-1 transcription. We have identified a second-generation deriva-
tive called 18BIOder as an inhibitor of HIV-1 Tat-dependent transcription in TZM-bl cells and a potent inhibitor of GSK-3
kinase in vitro. Structurally, 18BIOder is half the molecular weight and structure of its parental compound, 6BIO. More impor-
tantly, we also have found a different GSK-3 complex present only in HIV-1-infected cells. 18BIOder preferentially inhibits this
novel kinase complex from infected cells at nanomolar concentrations. Finally, we observed that neuronal cultures treated with
Tat protein are protected from Tat-mediated cytotoxicity when treated with 18BIOder. Overall, our data suggest that HIV-1 Tat-
dependent transcription is sensitive to small-molecule inhibition of GSK-3.
Combination antiretroviral therapies (cART) prolong the livesof HIV-1-infected subjects but are concomitantly limited to
virus-based inhibitors that primarily block various steps, includ-
ing reverse transcription and integration of proviral DNA, or pre-
vent the formation of functional viral particles. Despite the success
of cART in slowing disease progression and decreasing the inci-
dence of HIV-1-associated dementia (HAD), the percentage of
infected patients suffering from HIV-1-associated neurocognitive
disorders (HAND), which are characterized by cognitive, motor,
and behavioral anomalies, remains unchanged (1–3). Conse-
quently, epidemiological data suggest that cART provides partial
protection of HIV-1-infected individuals from neurological dam-
age (4, 5). A portion of the current research efforts focus on find-
ing novel host-based therapies that can provide viral inhibition in
tandem with protection of cells from apoptosis. Cytoprotective
effects are desirable in order to protect already depleted cell pop-
ulations and to counteract detrimental effects of viral proteins,
such as Tat and gp120 (Env), which are normally generated during
infection (6–11).
The HIV-1 transactivator Tat is an important regulatory pro-
tein that directs viral transcriptional elongation by association
with the transactivation response (TAR) RNA element present at
the transcriptional initiation site (positions 3 to 57) on the
HIV-1 long terminal repeat (LTR). The Tat/TAR complex is able
to recruit various critical host cell factors, such as the pTEF-b
complex (Cdk9/Cyclin T1), to the RNA polymerase II complex
that occupies the LTR (12–19). Due to its small size and stretch of
basic residues, Tat can be secreted into the extracellular environ-
ment, where it exerts various functional effects on bystander cells
(8, 20–26). The neurotoxic effects of HIV-1 are largely attributed
to the Tat and gp120 proteins (27, 28). For example, Cheng et al.
(27) demonstrated that exogenous Tat treatment could cause de-
polarization of human fetal neurons in culture, suggesting the Tat
protein may directly contribute to neurotoxicity. Similarly, gp120
treatment induced injury to primary rat dopamine cells and re-
duced dopamine transport, suggesting a neuropathological con-
sequence of gp120 (27), while this negative effect was prevented by
gp120 antibody. Moreover, studies carried out over the last 2 de-
cades link extracellular Tat to HIV-1 HAND, where Tat functions
as a neuroexcitatory toxin that plays a role in virus-mediated neu-
ronal dysfunction (29–33). Postulated mechanisms of Tat neuro-
toxicity include altered calcium homeostasis and calcium depen-
dence in fetal neurons (27, 34, 35), increased oxidative stress
resulting from direct injection of Tat into the intrastriatal space
(36), increased gliosis and glial infiltration (36–38), stimulation of
the glutamatergic system (39), increased nitric oxide production
in microglial cultures (40), and increased apoptosis from cell
damage and death following Tat exposure (34, 41). Moreover, the
paracrine-like function of Tat wields its effects on neuronal cells
and entails excitotoxic mechanisms possibly triggered in a recep-
tor-dependent manner (42). Although extracellular secretion of
HIV-1 Tat protein by infected T cells has been well documented
(20, 24) and is largely considered to play a role in HIV-associated
neuronal disease, secretion of Tat by infected primary macro-
phages and its contribution to neurotoxicity are not clear. Several
Tat targets have been previously described (43, 44) and include
N-methyl-D-aspartate (NMDA) receptors and GPCR activation
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(42), vascular endothelial growth factor 1 receptor (45), v integ-
rin subunit-containing receptors (43, 46, 47), low-density lipo-
protein receptor-related protein (48), and amino acid excitatory
receptors (29, 49, 50). Thus, Tat is an important neurotoxin in the
HIV-1-infected brain and a novel therapeutic target that could be
utilized in HIV-1 inhibition to counter the effects of Tat in the
brain.
To date, multiple drug candidates that counteract host-based
targets (51–59) or specifically target viral components (60–64)
have been examined. Several HIV-1 transcriptional inhibitors, in-
cluding K-12 and Ro24-7429, have undergone clinical trials and
have been determined not to be clinically efficacious (65–68).
More recent findings, however, indicate that novel virus- and
host-based inhibitors can inhibit HIV-1 transcription without af-
fecting normal cellular functions. Such compounds include
WP631, temacrazine, and various cyclin-dependent kinase (Cdk)
inhibitors (69–75). In the last 10 years, host-based therapies have
shed light on potential targets that had previously not been fully
recognized. For instance, robust glycogen synthase kinase-3
(GSK-3) inhibitors, such as lithium and valproic acid, have been
shown to protect against Tat- and gp120-mediated neurotoxicity
(59, 76, 77). Recently, small chemical molecules have taken the
spotlight due to their capacity for conferring both potent Tat-
dependent transcriptional inhibition and cytoprotection from
Tat-induced neurotoxicity through mechanisms that remain to be
determined (33, 78).
In this study, we present data on a small-molecule inhibitor
that both achieves Tat-dependent transcription inhibition and
protects cells from Tat-induced neurotoxicity. The small chemical
molecule inhibits GSK-3, an enzyme that has been associated
with HAND. We have characterized 18BIOder as an effective non-
cytotoxic HIV-1 Tat-dependent transcriptional inhibitor. In ad-
dition, we have described GSK-3 upregulation in HIV-1-in-
fected cells and the formation of new protein complexes during
infection. We demonstrate that our small-molecule compound
inhibits HIV-1 transcription by targeting this novel GSK-3 com-
plex present only in infected cells. Therefore, targeting the host
GSK-3 pathway can serve as an attractive strategy for the devel-
opment of novel host-based therapeutics that target both viral
transcription and neurotoxic side effects of HIV-1 infection.
MATERIALS AND METHODS
Cell culture and reagents. The human fetal microglial cell line CHME5 (a
generous gift from Pierre Talbot, Laboratory of Neuroimmunovirology,
INRS-Institute, Armand-Frappier, Canada) were grown and cultured to
confluence in Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, and 1%
streptomycin/penicillin (Gibco/BRL, Gaithersburg, MD, USA). CHME5
cells have been well characterized (79–81) and were obtained from em-
bryonic fetal human microglia through transformation with simian virus
40 (SV-40) T antigen (79, 80). TZM-bl and HLM-1 cells were obtained
from the AIDS Research and Reference Reagents Program (NIH, Be-
thesda, MD, USA). TZM-bl cells are engineered HeLa cells that express
CD4, CCR5, and CXCR4 and contain integrated reporter genes for firefly
luciferase and -galactosidase under the control of an HIV-1 long termi-
nal repeat (82). HLM-1 cells are HeLa-T4 cells containing one integrated
copy of the HIV-1 genome with a Tat-defective mutation at the first AUG
of the Tat gene. In the absence of stimulation, HLM-1 is completely neg-
ative for virus particle production, and viral transcripts are completely
absent (83). Suspensions of J1.1 and ACH2 cells and their uninfected
counterparts, Jurkat and CEM cells, as well as the promonocytic U1 cell
line and the corresponding uninfected U937 cell line, were cultured in
RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 1%
L-glutamine, and 1% streptomycin/penicillin. The J1.1 cell line is a Jurkat
E6.1 derivative chronically infected with HIV-1 (strain LAI) (84). ACH2
and J1.1 cells each contain a single integrated copy of the HIV-1 genome
(85), whereas U1 cells harbor two copies (one wild type and one mutant)
of the viral genome (strain LAV-1) in parental U937 cells (86). All cells
were incubated at 37°C and 5% CO2. AP-7 SV-40 T-antigen-transformed
olfactory neuronal cells (87) (a generous gift from Diane Griffin, Johns
Hopkins University, Baltimore, MD, USA) were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% FBS, 1% L-glutamine, and
1% streptomycin/penicillin at 33°C in 7% CO2. Differentiated AP-7
(dAP-7) cells were derived from the AP-7 cells in the cycling state by
placing them in differentiation medium composed of DMEM supple-
mented with insulin (2 g/ml), 40 M dopamine, and 200 M ascorbic
acid. The cells were allowed to differentiate at 39°C in 5% CO2 for 6 days
prior to use in experiments. The HIV-1 Tat protein was prepared as de-
scribed previously (88). Briefly, the Tat protein was expressed in Esche-
richia coli. Bacterial cells were sonicated and clarified by centrifugation
before being chromatographed on a Sephacryl S-200 column and then,
finally, purified on a reverse-phase high-performance liquid chromatog-
raphy (HPLC) column. Full-length Tat protein (amino acids [aa] 1 to 86)
was incubated with neuronal (dAP-7) cells in the presence or absence of
18BIOder. The effects of 18BIOder on Tat-mediated cell viability and cell
death were analyzed by CellTiter-Glo and DNA fragmentation assays,
respectively. Transcriptionally inactive Tat peptide containing a basic do-
main (aa 36 to 72) was used as a positive control for Tat-mediated neu-
rotoxicity (32).
Transfections and luciferase assay. TZM-bl cells were transfected
with pc-Tat (0.5 g) using the Attractene reagent (Qiagen, Chatsworth,
CA, USA) according to the manufacturer’s instructions. The next day, the
cells were treated with dimethyl sulfoxide (DMSO) or the indicated com-
pound at 1.0 M. Forty-eight hours post-drug treatment, firefly luciferase
activity was measured with the BrightGlo Luciferase Assay (Promega,
Madison, WI, USA), and luminescence was read from a 96-well plate on
an EG&G Berthold luminometer (Berthold Technologies, Oak Ridge, TN,
USA).
Cell viability assay. Fifty thousand cells per well were plated in a 96-
well plate and treated the next day with 1.0 or 10 M compound or
DMSO. Forty-eight hours later, CellTiter-Glo (Promega, Madison, WI,
USA) was used to measure viability following the manufacturer’s recom-
mendations. CellTiter-Glo is a luminescence assay used to measure cell
viability by ATP level. The reagent was added to the wells (1:1 [reagent-
medium]) and incubated at room temperature for 10 min protected from
light. The luminescence was detected using the GloMax-Multi Detection
System (Promega).
Small-molecule compounds. The selected 2nd-generation 6-bromo-
indirubin-3=-oxime (6BIO) derivatives used in this study were
6:6-bromo-5-methyl-1H-indole-2,3-dione 3-[(6-bromo-5-methyl-2-oxo-1,2-
dihydro-3H-indol-3-ylidene)hydrazone] (6BIOder), 10:5,7-dibromo-1H-in-
dole-2,3-dione 3-oxime (10BIOder), 18:6-chloro-7-methyl-1H-indole-2,3-di-
one 3-oxime (18BIOder), and 19:4-chloro-7-methyl-1H-indole-2,3-dione
3-oxime (19BIOder). All inhibitors were obtained from Hit2Lead (ChemBridge
Corporation, San Diego, CA, USA) and prepared in 10 mM stock solution dis-
solved in DMSO.
In silico docking of BIOders onto GSK-3. The small-molecule
docking simulations on GSK-3 were performed using the AutoDock
software package version 3.05 (Scripps Research Institute, La Jolla, CA,
USA). For GSK-3, the protein receptor, while held rigid, was taken from
Protein Data Bank (PDB) file 1UV5, and the Kollman charges were added.
PRODRG (89) was used to prepare the ligands, 6BIO, 6BIOder,
18BIOder, and 19BIOder. Mass-centered grid maps were generated with
0.15-Å spacing by the AutoGrid program only for the ATP pocket of
GSK-3, with default parameters. This grid was then used to dock the
above-mentioned ligands locally to the ATP pocket. A Lamarckian genetic
algorithm (LGA) scheme was chosen for conformational searching and
Guendel et al.
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optimization. For each receptor-ligand pair, 20 simulations with random
initial ligand conformation were performed with LGA. The complex con-
formation with the lowest binding free energy was used to visualize the
binding mode within the Chimera program (90), where only hydrogen
bonds were highlighted with distance. The schematic diagram of a more
detailed interaction network of the binding mode was generated by the
LIGPLOT program (91).
Reverse-transcriptase activity and p24 enzyme-linked immunosor-
bent assays (ELISAs). For reverse-transcriptase (RT) assays, supernatants
from infected cells (10 l) were incubated in a 96-well plate with RT
reaction mixture containing 1 RT buffer (50 mM Tris-HCl, 1 mM di-
thiothreitol [DTT], 5 mM MgCl2, 20 mM KCl), 0.1% Triton, poly(A) (10
to 2 U), poly(dT) (2 to 10 U), and [3H]TTP. The mixture was incubated
overnight at 37°C, and 5 l of the reaction mixture was spotted on a DEAE
filter mat paper (PerkinElmer, Shelton, CT, USA), washed four times with
5% Na2HPO4 and three times with water, and then dried completely. RT
activity was measured in a Betaplate counter (Wallac, Gaithersburg, MD).
Similarly, supernatants from infected cells were incubated in a 96-well
plate precoated with HIV-1 anti-p24 antibody following the manufactur-
er’s protocol (SAIC-NCI, Frederick, MD). Quantitative analysis of HIV-1
in the supernatant was performed based on a linear standard curve gen-
erated by the optical densities (ODs) of serial dilutions of known amounts
of p24 antigen.
Protein extracts and immunoblotting. Cells were collected, washed
once with phosphate-buffered saline (PBS), and pelleted. The cells were
lysed in a buffer containing Tris-HCl, pH 7.5, 120 mM NaCl, 5 mM
EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT, and one
tablet of Complete protease inhibitor cocktail per 50 ml. Lysis was per-
formed on ice, incubated on ice for 30 min, and spun at 4°C for 5 min at
14,000 rpm. The protein concentration for each preparation was deter-
mined with a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA). Cell extracts were resolved by SDS-PAGE on a 4 to 20% Tris-
glycine gel (Invitrogen, Carlsbad, CA, USA). Proteins were transferred to
polyvinylidene difluoride microporous membranes using the iBlot dry-
blotting system as described by the manufacturer (Invitrogen). The mem-
branes were blocked with Dulbecco’s PBS (0.1% Tween 20 plus 3% bovine
serum albumin [BSA]). Primary antibody against the specified protein
was incubated with the membrane in blocking solution overnight at 4°C.
Antibodies against GSK-3 (1V001) and -actin (C-11) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). HIV-IG, the
anti-gp120 antibody (#3957), was obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH, and
contributed by Jonathan Karn. Membranes were washed twice with PBS
plus 0.1% Tween 20 and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 h in blocking solution. The presence
of secondary antibody was detected by SuperSignal West Dura Extended
Duration Substrate (Pierce, Rockford, IL, USA). Luminescence was visu-
alized on a Kodak 1D image station (Carestream Health, Rochester, NY,
USA).
Immunofluorescent staining. HLM-1 or HeLa-T4 cells were grown
on glass slides for 3 days in the presence or absence of 2 mM sodium
butyrate (NaB) or transfected with pc-Tat (5 g) using the Attractene
reagent (Qiagen). Cells were fixed for 1 h in 4% paraformaldehyde at
room temperature. The cells were then permeabilized with 0.5% Triton
X-100 in PBS for 20 min. Next, the cells were washed with PBS without
Mg2 and Ca2. After the wash, the cells were incubated with RNase A at
10 g/ml for 30 min at 37°C and washed again with PBS without Mg2
and Ca2. The cells were then blocked for 10 min at room temperature in
PBS plus 3% BSA. Primary antibodies for anti-GSK-3, GIT2 (sc-5416),
and Nef (sc-17437) were obtained from Santa Cruz. The antibodies were
incubated in fresh blocking buffer at 37°C for 1 h and washed 3 times for
3 min each time in 300 mM NaCl with 0.1% Triton X-100. Alexa Fluor 488
goat anti-rabbit (A11008; Invitrogen) and Texas Red goat anti-mouse
(T862; Invitrogen) at a dilution of 1:200 were used as secondary antibod-
ies and treated in the same manner as the primary antibody. DAPI (4=,6-
diamidino-2-phenylindole) (dilution, 1:1,000) was used to visualize nu-
clei. Fluorescence microscopy was carried out using a Nikon Eclipse 90i
microscope (Nikon Instruments Inc., Melville, NY, USA).
Size exclusion chromatography. Uninfected and infected log-phase
Jurkat and J1.1 T cells were pelleted for analysis. The cell pellets were
washed twice with PBS without Mg2 and Ca2 and resuspended in lysis
buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 5 M methylenedi-
aminetetraacetic acid, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1.0
mM DTT, and one Complete protease cocktail tablet per 50 ml) and
incubated on ice for 20 min, with gentle vortexing every 5 min. The lysates
were then centrifuged at 4°C at 10,000 rpm for 10 min. The supernatants
were transferred to a fresh tube, and protein concentrations were deter-
mined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA).
For each cell line, 2.5 mg of protein was brought up to 1.0-ml total volume
using chromatography running buffer (0.2 M Tris-HCl, pH 7.5, 0.5 M
NaCl, and 5% glycerol). The lysates were run on a Superose 6 10/300 size
exclusion chromatography column (GE Healthcare Bio-Sciences, Upp-
sala, Sweden) using the ÄKTA Purifier system (GE Healthcare Bio-Sci-
ences, Piscataway, NJ, USA). A quarter-inch gap was introduced into the
top of the Superose 6 column to better separate low-molecular-weight
complexes from fractions eluting off the far-right side of the chromato-
gram. After sample injection (using a 1-ml loop), the running buffer was
set at a flow rate of 0.3 ml/minute, and 0.5-ml fractions of the flowthrough
were collected at 4°C for a total of approximately 60 fractions. Every 5th
fraction was acetone precipitated (250 l) using 4 volumes of ice-cold
100% acetone with incubation for 15 min on ice. The lysates were centri-
fuged at 4°C for 10 min at 14,000 rpm, the supernatants were removed,
and the pellets were dried for about 10 min at 95°C. The pellets were
resuspended in Laemmli buffer and analyzed by immunoblotting with
GSK-3 and actin antibodies (Santa Cruz).
Mass spectrometry. Fractions corresponding to the medium- and
low-molecular-weight GSK-3 complexes were immunoprecipitated
with an anti-GSK-3 antibody. The immunoprecipitated material was
eluted from the A/G beads (Calbiochem). Identification of the peptides
was performed with an LTQ tandem mass spectrometer (MS-MS)
equipped with a reverse-phase liquid chromatography (LC) nanospray
(Thermo Fisher Scientific, Huntsville, AL, USA). The reverse-phase col-
umn was slurry packed in house with 5-m, 200-Å-pore-size C18 resin
(Michrom Bioresources, Auburn, CA) in a 100-m by 10-cm fused silica
capillary (Polymicro Technologies, Lisle, IL) with a laser-pulled tip. After
a sample injection, the column was washed for 5 min at 200 nl/minute
with 0.1% formic acid; peptides were eluted using a 50-min linear gradi-
ent from 0 to 40% acetonitrile and an additional step of 80% acetonitrile
(all in 0.1% formic acid) for 5 min. The LTQ MS was operated in a data-
dependent mode in which each full MS scan was followed by five MS-MS
scans where the five most abundant molecular ions were dynamically
selected and fragmented by collision-induced dissociation using normal-
ized collision energy of 35%. Tandem mass spectra were matched against
the National Center for Biotechnology Information mouse database with
SEQUEST BioWorks software (Thermo Fisher Scientific) with full tryptic
cleavage constraints and static cysteine alkylation by iodoacetamide. For a
peptide to be considered legitimately identified, it had to be the number
one matched and had to achieve cross-correlation scores of 1.9 for
[MH]1, 2.2 for [M2H]2, and 3.5 for [M3H]3 with a 	Cn value
of 
0.1 and a maximum probability of randomized identification of 0.01.
RNA extraction, RT-PCR, and qRT-PCR. For mRNA analysis of
Cdk9-related genes following drug treatments, total RNA was isolated
from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) ac-
cording to the manufacturer’s protocol. Five hundred nanograms of total
RNA was used to generate cDNA with the iScript cDNA Synthesis kit
(Bio-Rad) using oligo(dT) reverse primers. Cdk9-responsive gene prim-
ers have been previously described (92). RNA was analyzed by quantita-
tive RT-PCR (qRT-PCR). qRT-PCR assays were performed using the ABI
Prism 7000 and Invitrogen’s RNA UltraSense one-step quantitative-RT-
PCR system. The cycling conditions were as follows: 1 cycle at 50°C for 15
Neuroprotective GSK Inhibitor Blocks HIV-1 Replication
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min, 1 cycle at 95°C for 2 min, and 40 cycles at 95°C for 15 s and 53°C for
30 s. The absolute quantification was calculated based on the threshold
cycle (Ct) relative to the standard curve.
Immunoprecipitation and in vitro kinase assay. For immunopre-
cipitation (IP), select fractions obtained from size exclusion chromatog-
raphy were divided into equal parts and immunoprecipitated overnight at
4°C with GSK-3 or normal mouse IgG (Santa Cruz) antibody. The next
day, the complexes were precipitated with A/G beads (Calbiochem, La
Jolla, CA, USA) for 2 h at 4°C. IPs were washed twice with appropriate
TNE buffer (0.5 ml/wash) and kinase buffer (0.5 ml/wash). Reaction mix-
tures (20 l) contained TTK kinase buffer with 50 mM HEPES, pH 7.9, 10
mM MgCl2, 6 mM EGTA, 2.5 mM dithiothreitol, and -
32P (0.2 mM; 1
Ci). Phosphorylation reactions were performed with IP material and
200 ng of glycogen synthase peptide 2 (12-241; Millipore, Temecula, CA,
USA) as the substrate. Reaction mixtures were incubated at 37°C for 1 h,
stopped by the addition of 1 volume of Laemmli sample buffer containing
5% -mercaptoethanol, and analyzed by SDS-PAGE on a 4 to 20% gel.
The gels were stained, destained, dried, and subjected to autoradiography.
Quantitation was performed using Molecular Dynamics PhosphorImager
software (Amersham Biosciences, Piscataway, NJ, USA).
Nanoparticle enrichment of gp120 from primary macrophage cell
culture supernatants. The nanoparticles NT082 (Cibacron Blue F3G-A)
and NT084 (Acid Black 48) were generously provided by Ceres Nanosci-
ences. The nanoparticles were synthesized as previously described (93,
94). Briefly, core shells were generated in the following manner: N-iso-
propylacrylamide (NIPAm), N=N-methylene bisacrylamide (BIS), and
acrylic acid (AAc) or allylamine (AA) were polymerized via precipitation
polymerization. The NIPAm-Bis-AAc core shell of NT084 was covalently
functionalized with amino dyes by an amidation reaction in dimethylfor-
mamide in the case of Acid Black 48. The NIPAm– co-AA core shell of
NT082 was functionalized with Cibacron Blue F3G-A in a mixture of
sodium carbonate and water. To prepare cell culture supernatants for
downstream Western blot analysis of gp120 and Tat, we generated a 30%
slurry of both NT082 (Cibacron Blue F3G-A) and NT084 (Acid Black 48)
in RPMI. We then added this slurry (35 l) to HIV-1 89.6-infected pri-
mary macrophage culture supernatants (500 l) pooled from three do-
nors. After rotation for 30 min at 25°C, samples were centrifuged at 10,000
rpm for 5 min. The supernatants were aspirated, and samples were washed
twice with RPMI. After a final centrifugation at 10,000 rpm for 5 min,
Laemmli buffer (10 l) was added to elute materials off the nanoparticles.
The nanoparticles were incubated at 20°C for 10 min and then vortexed
and heated at 95°C for 5 min. Next, the nanoparticles were centrifuged at
10,000 rpm for 5 min, and the entire volume of Laemmli buffer was loaded
onto the gel.
Exosome isolation. To collect and prepare exosomes for downstream
cytokine array analysis, we purified the exosomes using ExoQuick reagent
(EXOQ5A-1; System Biosciences, Mountain View, CA, USA) according
to the manufacturer’s instructions. Briefly, pooled primary cell culture
supernatants (1.5 ml) were incubated with ExoQuick reagent (750 l),
and the two components were incubated overnight at 4°C. The next day,
the exosomes were pelleted by centrifugation at 5,000 rpm and resus-
pended in PBS (25 l) prior to use in cytokine assays.
Animal experiments. All mice used in the study were maintained
within the National Center for Biodefense and Infectious Disease’s breed-
ing colony (George Mason University, Manassas, VA, USA). All experi-
ments were carried out in biosafety level 2 (BSL-2) facilities and in accor-
dance with the Guide for the Care and Use of Laboratory Animals
(Committee on Care And Use of Laboratory Animals of the Institute of
Laboratory Animal Resources, National Research Council; NIH Publica-
tion no. 86-23, revised 1996). NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ mice
were obtained from the Jackson Laboratory (Bar Harbor, ME, USA;
007799) and were humanized as described previously (74). Briefly, neo-
natal animals were sublethally irradiated. The next day, the mice were
intraperitoneally implanted (100 l) with approximately 1  105 human
cord blood-derived CD34 hematopoietic stem cells (2C-101B; Lonza,
Walkersville, MD, USA). The cells were allowed to differentiate for 2 to 3
months. Five groups of two animals each were injected subcutaneously
with vehicle (DMSO) or 1.0 mg/kg of body weight and 10 mg/kg of two
drugs (18- and 19BIOder) 1 day prior to infection. The animals were
subsequently infected subcutaneously with the dual-tropic HIV-1 89.6
(100 l) and then further injected subcutaneously with the respective
doses of drugs. Blood samples were collected 14 days postinfection, and
serum was separated using Sarstedt Microvette 200 Z-Gel (20.1291;
Sarstedt AG & Co., Nümbrecht, Germany) for downstream assays. An
additional two groups of two animals each were subcutaneously injected
with DMSO or 1.0 mg/kg 18BIOder 1 day prior to infection, subsequently
infected subcutaneously with HIV-1 89.6, and then further treated with
18BIOder (1.0 mg/kg) at days 2, 5, 8, and 22. Blood was collected at days
14, 18, 25, and 29, and serum was separated as described above for down-
stream assays.
RESULTS
18BIOder inhibits HIV-1 Tat-dependent transcription. We pre-
viously identified the GSK-3 inhibitor 6BIO as a potent HIV-1
LTR transcriptional inhibitor by performing a high-throughput
screen for Tat-dependent transcription inhibitors from Lopac-
Sigma-Aldrich (1,280 compounds) and Spectrum-Microsource
(2,000 compounds) (33). In order to identify more potent 6BIO
analogs, a Hit2Lead compound query based on chemical structure
yielded 38 commercially available derivatives. During HIV-1 tran-
scriptional inhibition studies, two compounds of particular inter-
est were identified as possible regulators of Tat-activated tran-
scription. Both derivatives 18 and 19 are composed of half the core
structure of the parent compound, 6BIO, differing only in the
location of the chlorine R group. These analogs were tested at 1.0
M in a luciferase reporter gene system, scoring for activity
against Tat-dependent HIV-1 LTR transcription. TZM-bl cells
were transfected with Tat, followed by treatment with the parental
(6BIO) and second-generation (BIOder) compounds. The results
in Fig. 1A show luciferase activity assays performed in TZM-bl
cells 2 days posttreatment. The data indicated that derivative 18
inhibited HIV-1 LTR Tat-dependent transcription more effi-
ciently than 6BIO (6.7-fold and 1.7-fold decreases, respectively),
whereas derivative 19 did not show any inhibitory effect. We then
compared the inhibitory effects of 6BIO and its derivatives against
both HIV-1 and Venezuelan equine encephalitis virus (VEEV).
We used VEEV, since the 6BIOder compound was previously
shown by our group to significantly inhibit viral replication (95).
Quantification of previously obtained data (33, 95) in Fig. 1B in-
dicated that 18BIOder was effective in inhibiting Tat-dependent
HIV-1 transcription (
75% inhibition) but ineffective in VEEV
infection (no inhibition). Likewise, 19BIOder moderately inhib-
ited VEEV replication in vitro (50 to 75% inhibition) but had
minimal effect on HIV-1-activated transcription (5% inhibi-
tion). These findings indicate that although BIOder may be an
effective inhibitor of both viruses, only a few derivatives may be
selective against each virus in vitro.
18BIOder is a cytoprotective small-molecule inhibitor.
GSK-3 inhibitors have been shown to have prosurvival activity
and to regulate cell proliferation in various cell types (96–99). In
order to exclude potential cytotoxicity of our compounds, we first
assessed the effects of 18BIOder on cell viability in various cell
lines, including uninfected (CEM and Jurkat) and HIV-1-infected
T cells (ACH2 and J1.1) and monocytes (U937 and HIV-1-in-
fected U1). Flavopiridol (flavo) (100 nM), a well-characterized
pharmacological Cdk9 inhibitor, was used as a positive control for
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HIV-1 transcriptional inhibition in these assays (reference 100
and data not shown). The results in Fig. 2A indicate that the con-
centrations used in our transcriptional inhibition assays show
minimal compromise in cell viability by 18BIOder in either unin-
fected or infected cell lines. Statistical significance was determined
by Student’s t test. Significant P values were observed only when
DMSO (lane 2) was compared to18BIOder (lane 3) in the left
panel (P  0.013) and 18BIOder (lane 4) in the middle panel (P 
0.046). To further characterize the effect of 18BIOder on cell via-
bility, we performed flow cytometry analysis of Jurkat cells treated
with 1.0 and 10 M 18- and 19BIOder. The cells were treated with
each drug, maintained for 3 days, and collected for analysis. The
results in Fig. 2B showed that there is no increase in the sub-G1
population with 18BIOder treatment. In contrast, there is a 10 to
25% increase with 19BIOder treatment, suggesting increased
death in these cells. The cell cycle profile was not affected by drug
treatment compared to the untreated control (data not shown).
Next, we were interested in determining the effect of 18BIOder
treatment in primary human cells. Primary macrophages were
infected with HIV-1 89.6 and treated with 10 M on the day of
infection, as well as every 2 days postinfection (a total of 3 treat-
ments). The results in Fig. 2C showed that after receiving three
treatments of 18BIOder or 6BIOder, there was no significant loss
of cell viability at day 6 posttreatment in cells from three different
donors. The effect of 18BIOder on primary macrophages was fur-
ther analyzed by staining these cells with propidium iodide (PI)
and measuring apoptosis by flow cytometry. As shown in Fig. 2D,
there was no increase in the sub-G1 cell population with 18BIOder
treatment compared with DMSO. Collectively, these results indi-
cate that 18BIOder can inhibit HIV-1 transcription without in-
ducing cellular toxicity in either cell lines or primary cells.
18BIOder inhibits HIV-1 replication in a dose-dependent
manner. We next examined whether 18BIOder was effective in
inhibiting HIV-1 replication in chronically infected cell lines. J1.1
cells were treated with vehicle (DMSO) or two concentrations (1.0
and 10 M) of 18BIOder and 19BIOder. These cells are chroni-
cally infected and produce high viral titers in the supernatant
without cell death. Cells were treated with each drug and main-
tained for 6 days, and the supernatants were collected for RT anal-
ysis. As shown in Fig. 3A, although not statistically significant (by
the Student t test), multiple treatments of 10 M 18BIOder inhib-
ited virus replication by almost 50% (P  0.12). Interestingly,
there was no compromise in the viability of these cells when
treated with 18BIOder as tested by CellTiter-Glo assays (Fig. 3B).
While flavo treatment decreased cell viability to a moderate level,
the viability of nucleoside RT inhibitor (NRTI)-treated cells was
markedly reduced. To determine the levels of viral replication
inhibition in primary cells, peripheral blood mononuclear cells
(PBMCs) from 3 separate donors were activated with interleukin 2
(IL-2)-phytohemagglutinin (PHA) for 3 days prior to infection
with HIV-1 89.6 and treated only once with 0.01, 0.1, and 1.0 M
18BIOder. The results in Fig. 3C showed a dose-dependent de-
crease of viral replication in PBMCs from all 3 donors as measured
by p24 ELISA at day 6 postinfection. The levels of 18BIOder inhi-
FIG 1 18BIOder inhibits HIV-1 Tat-dependent transcription. (A) TZM-bl
cells were transfected with 0.5 g of Tat plasmid and treated the next day with
DMSO, 6BIO, and 18- and 19BIOder (1.0 M). The cells were processed 48 h
post-drug treatment for luciferase assays. The assays were performed in trip-
licate, and average values plus standard deviations are shown. Statistical sig-
nificance was determined by Student’s t test. RLU, relative light units. (B)
Summary of virus-inhibitory properties of sample 6BIO second-generation
derivatives against VEEV and HIV-1, and compound structures depicting the
structural variance of 6BIOder, 6-bromo-5-methyl-1H-indole-2,3-dione
3-[(6-bromo-5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazone];
10BIOder, 5,7-dibromo-1H-indole-2,3-dione 3-oxime; 18BIOder, 6-chloro-
7-methyl-1H-indole-2,3-dione 3-oxime; and 19BIOder, 4-chloro-7-methyl-
1H-indole-2,3-dione 3-oxime. The percent inhibition of viral replication
(VEEV) and transcription (HIV-1) was quantified and categorized based on
previously published data (33, 95). Briefly, U87MG astrocytes were pretreated
for 2 h with DMSO or BIO (5, 2.5, or 1.25 M), infected with VEEV TC-83 at
a multiplicity of infection (MOI) of 0.1, and posttreated with the compounds.
Twenty-four hours postinfection, the viral supernatants were collected and
assayed for viral replication by plaque assays. For HIV-1 studies, TZM-bl cells
were processed as previously described (33). The data are representative of
three technical triplicates and at least 2 biological replicates.
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bition were analyzed by comparing them with DMSO treatment
using the Student t test. Statistically significant virus inhibition
was achieved with both 0.1 and 1.0 M concentrations of
18BIOder (P  0.030 and 0.018, respectively). There was no sig-
nificant loss in cell viability with 18BIOder treatment in infected
PBMCs compared with DMSO treatment (Fig. 3D). Collectively,
these data show suppression of viral replication in the absence of
cytotoxicity.
GSK-3 expression is upregulated in HIV-1-infected cells.
We have previously shown that 6BIOder inhibits GSK-3 both in
vitro and in vivo (33, 95). We next examined the effects of GSK-3
in various uninfected and infected pairs of T cells and monocytes
using Western blot analysis. They included the uninfected cell
lines Jurkat, CEM, and U937 and the HIV-1-infected cell lines
J1.1, ACH2, and U1. We further utilized monocytoid cells (U937
m/U1 m) by inducing monocyte pairs with phorbol myristate
acetate (PMA) (101, 102). The results in Fig. 4A indicate that
GSK-3 levels were generally higher (2- to 5-fold increase) in
HIV-1 chronically infected cells compared to uninfected cells. En-
dogenous GSK-3exists within both active and inactive complexes in
the cytoplasm (103). We therefore asked whether GSK-3 localiza-
tion was differently affected in HIV-1-infected cells. For that, we uti-
lized a fractionation of cytoplasmic versus nuclear extracts and also
performed localization assays using confocal microscopy. The results
in Fig. 4B indicate that there was more GSK-3 in the cytoplasm
(4-fold increase compared to uninfected cells) and to a lesser extent
FIG 2 Lack of cellular toxicity when using 6BIO derivatives. (A) A panel of uninfected and infected cell pairs, including CEM and ACH2 (T cells), Jurkat and J1.1
(T cells), and U937 and U1 (monocytes), were treated with vehicle or 1.0 M or 10 M 18BIOder to determine possible compound toxicity in vitro. Cell viability
was determined by CellTiter-Glo assay. Statistical significance was determined by Student’s t test, and the significant P values are marked with asterisks. (B)
Uninfected Jurkat cells were treated with 1.0 M or 10 M 18- or 19BIOder for 72 h. The cells were processed with PI stain, and the cell cycle was analyzed by
flow cytometry. The percent sub-G1 (apoptosis) population is plotted to visualize the cell death detected. (C) Primary macrophages from three donors were
infected with HIV-1 89.6 by spinoculation and treated with DMSO or 10 M 18BIOder or 6BIOder on the day of infection, as well as every 2 days postinfection
(total, 3 treatments). Cell viability was determined by CellTiter-Glo assay 6 days posttreatment. (D) The HIV-1 89.6-infected primary macrophages from the
same donors were similarly treated with 10 M 18BIOder (as shown in panel C) and then stained with PI and analyzed by flow cytometry, and the percent sub-G1
(apoptosis) population was plotted. The experiments for panels A to D were performed in triplicate. The error bars indicate standard deviations.
Guendel et al.
1194 jvi.asm.org Journal of Virology















in the nucleus (2-fold increase compared to uninfected cells).
Localization of lamin A (nuclear) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (cytoplasmic) served as positive controls.
Finally, we utilized an HIV-1-infected silent cell line, HLM-1, which
harbors an integrated provirus containing a mutated Tat gene with a
triple termination codon (83). These cells can be induced to produce
virus using histone deacetylase (HDAC) inhibitors, such as NaB. We
therefore plated log-phase growing cells, induced virus production
using NaB, and looked for localization of GSK-3. The results in
Fig. 4C show that GSK-3 was mainly dispersed throughout the nu-
FIG 3 Effects of 18- and 19BIOder on HIV-1 replication. (A) Log-phase growing HIV-1-infected J1.1 T cells were treated once or every 2 days (total, 3
treatments) with 1.0 M and 10 M 18- or 19BIOder and vehicle. Flavopiridol (100 nM) was used as a positive control. The supernatants were processed for the
presence of RT activity at day 6 posttreatment. (B) J1.1 cells were treated once or every 2 days (total, 3 treatments) with 1.0 M and 10 M 18- or 19BIOder or
1.0 M 6Bioder. Flavopiridol (100 nM) and an NRTI cocktail (10 M) were used as controls. Cell viability was determined by CellTiter-Glo assay 6 days
posttreatment. (C) IL-2–PHA-activated PBMCs from 3 separate donors were pretreated once with 0.01, 0.1, or 1.0 M 18BIOder for 24 h and then infected with
HIV-1 89.6. The supernatants from infected PBMCs were collected for p24 ELISA 6 days postinfection. The statistical differences between 18BIOder inhibition
and DMSO treatment were analyzed by Student t test, and the significant P values are marked with asterisks. (D) PBMCs from 3 donors were similarly treated and
infected (as in panel C) with 18Bioder, and cell viability was determined by CellTiter-Glo assay 6 days postinfection. The error bars indicate standard deviations.
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cleus and, to a lesser extent, the cytoplasm prior to induction of
HLM-1 (Fig. 4C, I). However, after NaB treatment, the overall ex-
pression of GSK-3 was upregulated (Fig. 4C, II). The observed up-
regulation of GSK-3 in the cytoplasm was specific to virus activa-
tion, since treatment of HeLa-T4 with NaB did not result in
significantly altered GSK-3 expression (Fig. 4C, III and IV). Consis-
tent with these results, we found increased GSK-3 levels in both the
nucleus and cytoplasm of induced HLM-1 cells when counting more
than 100 cells per condition (Fig. 4D). To further reinforce that the
observed GSK-3 phenotype is specific to viral reactivation in
HLM-1 cells, we performed confocal analysis of GSK-3 and Nef as
viral markers in cells that had been treated with NaB or Tat (transfec-
tion). The GIT2 protein was used as a cytoplasmic positive-control
marker. The results in Fig. 4E showed that cells exhibiting altered
GSK-3 expression are positive for Nef expression, indicating active
viral expression in these cells. As expected, the untreated HLM-1 cells
did not show staining for GSK-3, GIT2, or Nef (Fig. 4F). Taken
together, these results are suggestive of altered GSK-3 dynamics
during HIV-1 infection, as indicated by increased protein expression
levels and intracellular distribution.
GSK-3 upregulation and complex redistribution in HIV-1-
infected cells. It is widely accepted that viral infection causes pro-
found changes in the dynamics of the host cell. For this reason, the
elucidation of novel protein complexes in infected but not in un-
infected cells is a great tool for the understanding of viral mecha-
nisms and the development of new host-based therapies. Based on
the observed GSK-3 upregulation and altered cellular distribu-
tion in infection, we next asked whether the virus could gener-
ate novel GSK-3 complexes that could serve as a target for
18BIOder. To this end, size exclusion chromatography serves as a
tool to efficiently fractionate functional protein complexes of in-
terest for further downstream analysis (95, 104, 105). In fact, in a
recent study, this technique was utilized to successfully discern
novel GSK-3 complex formation in VEEV-infected U87MG cells
(95). In order to determine the elution profile of GSK-3 in HIV-
1-infected cells, we performed size exclusion chromatography to
separate protein complexes, followed by Western blot analysis.
We prepared total protein extracts from matched parental unin-
fected Jurkat and infected J1.1 cell lines and loaded the samples on
a Superose 6 size exclusion column in the presence of a stringent
500 mM salt concentration. The high salt concentration provides
specificity for stable protein complexes. Samples were fraction-
ated in water-soluble buffer, followed by precipitation to concen-
trate protein fractions and remove excess salt. Roughly every 5th
fraction was assayed by Western blotting for the presence of
GSK-3 and -actin. The results in Fig. 5A show a dramatic dif-
ferential GSK-3 signature in the lower-molecular-weight frac-
tions between uninfected and infected cells. Uninfected cells
showed a predominant band with a molecular mass of 300 kDa
in fraction 35, most likely representing homo- or heterodimers
alongside other bound proteins. However, when utilizing the
HIV-1-infected cells, we observed a different distribution profile
of GSK-3. The infected J1.1 gel, lanes 7 to 11, showed significant
presence of GSK-3 in fractions 40 to 55 compared to uninfected
cells. Additionally, we observed increased expression and redistri-
bution of actin in infected cells. This is in agreement with HIV-1
dependence on the actin cytoskeleton, where the virus utilizes
actin to facilitate entry, reverse transcription, and nuclear migra-
tion for infection establishment (106). Interestingly, the levels of
lamin A and gelsolin were similar in the two cell types; however,
GAPDH levels slightly increased in the Jurkat cell uninfected frac-
tions 45 to 55 (data not shown). We next examined the GSK-3
expression profile in a set of other cells, and the results in Fig. 5B
indicate a similar pattern of GSK-3 redistribution observed in
paired monocytic uninfected and infected cells. Similar to the T
cell signature, GSK-3 protein is distributed to lower-molecular-
weight fractions in U1 cells compared to the uninfected U937
cells. The low-molecular-weight GSK-3 protein complexes
unique to the infected lysates were found in the fractions associ-
ated with the right-hand side of the A280 chromatogram (Fig. 5C).
Of interest, the total protein lysate eluted as a bell curve (Fig. 5C,
inset), with smaller amounts of proteins eluting in the high- and
low-molecular-weight regions and the majority of proteins elut-
ing around fraction 30 (data not shown). To further investigate
protein distribution changes, we concentrated a small sample of
neighboring relevant fractions of both Jurkat and J1.1 cell frac-
tionations, resolved them by SDS-PAGE, and silver stained the gel.
The results in Fig. 5D indicate that fractions 37 and 47 of unin-
fected and infected cells contain relatively similar amounts of total
protein. To further characterize these complexes, we performed
mass spectrometry analysis of J1.1 fractions 37 and 47. Briefly,
GSK-3 was immunoprecipitated from these fractions and sub-
jected to LC–MS-MS. Our data suggest that GSK-3 found in
lower-molecular-weight fractions (fraction 47) is mostly present
as free enzyme, while GSK-3 in larger complexes (fraction 37)
interacts with putative binding partners. Identified binding pro-
teins included activating signal cointegrator 1 (ASC-1), a complex
known to enhance transactivation of NF-B, SRF, and AP1 (107),
all of which are factors linked to HIV-1 activation. To examine
interaction between GSK-3 and ASC-1, we performed GSK-3
immunoprecipitation from Jurkat and J1.1 whole-cell lysates, in
addition to J1.1 fractions 37 and 47. The results in Fig. 5E indicate
FIG 4 GSK-3 expression is upregulated in HIV-1 infection. (A) To assess GSK-3 expression in a series of uninfected and infected cell pairs, 100 g of
whole-cell extract from Jurkat/J1.1, CEM/ACH2, U937/U1, and PMA-treated U937/U1 monocytoid cells (U937 m/U1 m) were run on 4 to 20% SDS-PAGE
and immunoblotted against GSK-3 and -actin as a loading control. Western blots were performed in duplicate. (B) Cytosolic and nuclear extracts were
prepared from 5  106 Jurkat and J1.1 cells. The extracts were analyzed by Western blotting using anti-GSK-3. Actin was utilized as a loading control. Lamin
A and GAPDH were used as nuclear and cytoplasmic controls, respectively. Western blots were performed in duplicate. (C) HeLa-T4 and HLM-1 cells were
grown on coverslips in the presence or absence (mock) of NaB for 72 h. The cells were stained for GSK-3 and visualized with confocal microscopy. Cellular
GSK-3 protein staining is represented in green in the cytoplasm, and nuclei were stained with DAPI (blue). Row I shows HLM-1 mock cells (control), row II
shows HLM-1cells induced with NaB, row III shows HeLa-T4 mock cells (control), and row IV shows HeLa-T4 cells treated with NaB. Upregulated GSK-3
levels observed in induced HLM-1 (activated virus) are indicated with white arrows in row II (merge). (D) HLM-1 cells were treated with NaB for 72 h. GSK-3
localization was determined by confocal microscopy as in panel C. One hundred cells per condition were counted and scored for the presence of GSK-3 distribution
and upregulation in HLM-1 and HeLa-T4 cells. Data collection was performed in triplicate. (E) HLM-1 cells were grown on coverslips in the presence of NaB
or transfected Tat for 72 h. The cells were stained for GSK-3, Nef, and GIT2 and were visualized with confocal microscopy. Cellular GSK-3 protein staining
is represented in green, Nef and GIT2 are red, and nuclei were stained with DAPI (blue). GIT2 served as a cytoplasmic protein control. (F) As background control,
HLM-1 cells were also stained for Nef, GIT2, or GSK-3 in the absence of NaB treatment or Tat transfection. NS, nonspecific.
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FIG 5 Presence of novel GSK-3 complexes in HIV-1-infected cells. (A) Samples from uninfected Jurkat (top) and infected J1.1 (bottom) T cells were loaded
in a size exclusion chromatography column and separated in the presence of 500 mM salt buffer. No detergent was used during fractionation. A sample (250 l)
of every 5th fraction from 10 to 55 was acetone precipitated and resuspended in 30 l of Laemmli buffer. Fifteen microliters was run on a gel for Western blotting
for the presence of GSK-3 and -actin. Western blots were performed in duplicate. (B) Similar to panel A, uninfected U937 (top) and infected U1 (bottom)
monocytic cells were loaded in a size exclusion chromatography column and separated. Western blots were performed in duplicate. (C) Two and a half milligrams
of J1.1 WCE (lysis buffer described in Materials and Methods) was brought up to 500 l in running buffer and processed through the Superose 6 column as
described in Materials and Methods. The chromatogram shows a sample A280 trace of the processed WCE sample. The inset depicts the overall bell-shaped elution
profile of the WCE as confirmed through Western blots. The red box indicates the tailing fractions in which the low-molecular-weight (LMW) complexes specific
to the infected J1.1 WCE were contained. (D) Fifty microliters of J1.1 fractions 37 and 47 was acetone precipitated and processed as in panel A. Fifteen microliters
was run on a gel and silver stained to visualize the total protein content in these relevant fractions as a measure of loading control. (E) GSK-3 was immuno-
precipitated from J1.1 whole-cell lysates and fractions 37 and 47. Eluted samples were subjected to mass spectrometry analysis. ASC-1 was a novel candidate
protein identified by LC-MS analysis. To verify this putative interaction, GSK-3 was immunoprecipitated from Jurkat and J1.1 whole-cell lysates and J1.1
fractions 37 and 47. IP material was run on a gel and Western blotted for ASC-1 and GSK-3. Western blots were performed in duplicate. NS, nonspecific; WCE,
whole-cell extract.
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that there is increased enrichment of ASC-1 in J1.1 cell lysates and
fractions compared to Jurkat cells (compare lanes 3, 5, and 7 to 8),
suggesting altered and novel binding dynamics between GSK-3
and ASC-1 in infection. Collectively, these results imply that novel
GSK-3 complexes are formed during HIV-1 infection in both T
cells and monocytic lines.
18BIOder does not inhibit cellular gene expression in the ab-
sence of Tat and is specific to GSK-3. It is well known that
HIV-1 Tat-dependent transcription requires canonical cellular
transcriptional machinery, such as p-TEFb (Cdk9/cyclin T1), for
promoter activation and transcriptional elongation. We have
shown that 18BIOder is able to inhibit HIV-1 transcription. In
order to determine that this effect was not due to the general
downregulation of cellular gene expression in drug-treated cells,
we sought to determine if 18BIOder treatment was inhibitory to
cellular genes that require p-TEFb. The results in Fig. 6A show
RT-PCR amplifications of CAD, CIITA, cyclin D1, and PBX-1, a
set of genes that require Cdk9/cyclin T1for their transcription
(108–110). None of these genes showed a decrease in transcription
in various cell types, including 293T cells, CHME5 human micro-
glial cells, and Jurkat T cells. To verify these RT-PCR findings in a
more quantitative manner, we performed a representative qRT-
FIG 6 18BIOder does not inhibit cellular gene expression in the absence of Tat and is specific to GSK-3. (A) Total RNA was isolated from cells treated with
18BIOder (1.0 and 10 M for 293T cells and 1.0 M for CHME5 and Jurkat cells) using RNeasy Mini Kit extraction. A total of 500 ng was used to generate cDNA
with the iScript cDNA synthesis kit using oligo(dT) reverse primers. The primers for PCR were CAD, CIITA, cyclin D1, PBX-1, and GAPDH as a control. (B) A
representative panel of intracellular RNA levels of PBX-1 were determined by qRT-PCR using total RNA extracted from cells shown in panel A. The error bars
indicate standard deviations. (C) GSK-3 IPs from fractions 35 and 50 (250 l each) were mixed with 5 g of GSK-3 or IgG (control immunoprecipitation)
antibodies overnight and washed the next day, first with RIPA buffer (1) and then TNE and 0.1% NP-40 (2), followed by kinase buffer (3), prior to addition
of substrate and [-32P]ATP. Samples were run on a gel, stained, destained (over 4 h), dried, and then exposed to a phosphorimager cassette. (D) IP/kinase
reactions were treated with 18BIOder (10 nM) in vitro during the kinase reaction. Samples were run on a gel and exposed to a phosphorimager cassette. The kinase
assay was quantified by densitometry and expressed as percent kinase activity compared to the immunoprecipitated Jurkat fraction 35 GSK-3 activity. (Bottom)
Coomassie gels show p-Gly pep 2 substrate stains.
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PCR on the same RNA used in Fig. 6A. The results in Fig. 6B
showed that for both 293T and Jurkat cells there was no decrease
in PBX-1 transcripts upon treatment with 10 M 18BIOder.
These results further reinforce the notion that the transcriptional
inhibition caused by 18BIOder may be specific to the HIV-1 pro-
moter.
We next examined the functional effects of various GSK-3
complexes from both uninfected and infected cells. GSK-3 is
known to be regulated by pathways that include phosphorylation
of the enzyme, protein complex formation, and intracellular lo-
calization (111). Therefore, we asked whether GSK-3 found in
these small and medium-size complexes were active and whether
18BIOder was capable of inhibiting these GSK-3 complexes in
vitro. To that end, we performed GSK-3 immunoprecipitation
from fractions 35 (medium size) and 50 (small) from both unin-
fected and infected cells and used the immunoprecipitated mate-
rial in an in vitro kinase assay with glycogen synthase peptide 2 as
the substrate. The results in Fig. 6C indicated that GSK-3 present
in fractions 35 from both uninfected and infected cells was active.
In addition, these results also confirm the absence of GSK-3 in
Jurkat fraction 50 (6% activity) and increased GSK-3 present
in J1.1 fraction 50 (32% activity). We next used 18BIOder in ki-
nase assays and found that upon treatment of the immunoprecipi-
tated material with 18BIOder (10 nM), there was little inhibition
of kinase activity from Jurkat fraction 35 (33% activity) (Fig.
6D, compare lanes 1 and 2). Interestingly, treatment of J1.1 frac-
tions 35 (lanes 3 and 4) and 50 (lanes 5 and 6) showed more
sensitivity to 18BIOder, with 36% and 41% kinase inhibition, re-
spectively. Taken together, these data support the notion that
18BIOder transcriptional inhibition is specific to the GSK-3
present in HIV-1-infected cells.
18BIOder protects neuronal cultures from HIV-1 proteins
and cytokine toxicities. Currently, cART does not fully protect
against HAND. Recently, neuroimaging studies have shown the
presence of virus in the brain even at early stages of infection
(112). To date, there are very limited interventions available to
prevent HIV-1-associated neurotoxicity or dementia. Although
Nef, Rev, and Vpr have been linked to neurotoxicity, the neuro-
toxic effects of HIV-1 are largely attributed to gp120 and Tat pro-
teins (7, 9, 10, 27, 28, 113–115). Current cART treatment does not
block production of early viral proteins, such as Tat, even during
successful virus suppression, and thus, extracellular Tat released
into the extracellular space can exert neurotoxic effects on by-
stander cells (116, 117). However, the pivotal release of Tat by
infected cells and the consequent uptake by neurons remained
undefined until recently. Quantified neuronal uptake of circulat-
ing Tat was achieved by using high-performance capillary electro-
phoresis and was measured to 2 pg/ml in both a neuronal cell
line and primary cultures (23), highlighting the involvement of
Tat in HAND. Several GSK-3 inhibitors, such as cesium chloride
(118), lithium chloride (119), valproate (120), AR-A014418/
B6B30 (78), and 6BIOder (33), have been shown to confer neuro-
protection from Tat-induced neurotoxicity, though efforts to
fully halt Tat-mediated neurodegeneration both in vitro and in
vivo have failed (23). In order to further explore the role of
18BIOder in a more relevant system, we obtained primary mac-
rophages from three independent donors. The macrophages were
spinoculated with HIV-1 89.6 and subjected to treatment with 10
M 18BIOder or 6BIOder at days 1, 3, and 5 postinfection, and
cells and supernatants were harvested at day 6 postinfection. The
results shown in Fig. 7A indicate that both 18- and 6BIOder dra-
matically reduced HIV-1 replication in macrophages from two of
three donors (donors 1 and 3) as Env RNA copies measured by
qRT-PCR. Unexpectedly, 6BIOder was more effective in reducing
virus replication in the macrophages from donor 2. To examine
the potential neurotoxin contents of these infected macrophages,
we performed 2 separate assays. First, we pooled supernatants
from new donors, 1 and 3. The supernatants were enriched for
gp120 and Tat using the NT082 (Cibacron Blue F3G-A) and
NT084 (Acid Black 48) nanoparticles (Ceres Nanosciences, Ma-
nassas, VA, USA), which we have shown to specifically bind and
trap HIV-1 gp120 (data not shown) and Tat (121) from complex
and dilute solutions. A 30% slurry of nanoparticles was added to
each indicated fraction at equal volumes. Samples were incubated
with rotation for 30 min at room temperature, spun down, and
aspirated. Nanoparticles were resuspended in an equal volume of
Laemmli buffer. Figure 7B shows the presence of gp120 and Tat, as
detected by Western blotting in infected donor samples, with per-
cent densitometry counts for gp120 displayed above the capture.
18BIOder-treated macrophages (Fig. 7B, lane 4) showed a 28%
decrease in gp120 abundance compared to untreated cells (Fig.
7B, lane 2); however, there was no decrease in Tat levels, and
therefore, the inhibition may be occurring at the level of Tat-
activated transcription, resulting in lower levels of singly spliced
messages, such as Env. Media from uninfected cells were used in
nanotrap experiments as a negative control (Fig. 7B, lane 1).
In addition to virus-derived neurotoxins, cellular factors, such
as inflammatory chemokines and cytokines released by infiltrating
FIG 7 18BIOder protects microglial and neuronal cultures from the HIV-1 Tat protein. (A) Primary macrophages from three donors were infected with HIV-1
89.6 by spinoculation. After overnight recovery, the cells were treated with DMSO or 10 M 18BIOder or 6BIOder, and thereafter every 2 days postinfection
(total, 3 treatments). The supernatants were collected, and virus production was measured by analyzing Env RNA copies using qRT-PCR at day 6 postinfection.
Triplicate samples from donors 1 and 3 and a single sample from donor 2 were analyzed. Insufficient material was recovered from donor 2 for triplicate analysis.
(B) Supernatants collected from the infected macrophages at day 6 postinfection as in panel A were pooled and subjected to nanoparticle capture of gp120 and
Tat by using NT082 (Cibacron Blue F3G-A) and NT084 (Acid Black 48). Nanoparticle contents were resuspended in 10 l Laemmli buffer and run on a gel.
Membranes were immunoblotted with HIV-1-infected human immune serum (for gp120) and -Tat mouse monoclonal antibody. Normal human serum and
mouse IgG were used as isotype controls. Densitometry counts were performed for -gp120 blotting, and the effects of 18Bioder were compared. Western
blotting was performed in duplicate. (C) Supernatants from panel A were subjected to exosome purification using Exoquick reagent following the manufacturer’s
instructions. Exosome material obtained from the infected macrophage supernatants were analyzed for cytokine expression using a custom human cytokine
array (RayBio Human Cytokine Array 1) following the manufacturer’s instructions. (D) dAP-7 neuronal cells were differentiated for 6 days and treated with 18-
or 6BIOder (0.1 M) for 1 h at 39°C prior to 18 h of exposure to 500 nM Tat1-86. Cell viability was tested using a CellTiter-Glo assay to determine the
cytoprotection effect of BIOders. The quantifications are based on triplicate experiments, and statistical analyses were performed between DMSO and Tat1-86
treatments and also between Tat1-86 and BIOder treatments using Student’s t test, and a significant P value is marked by an asterisk. Transcriptionally inactive Tat
peptide containing the essential basic domain (positive control) and BSA (negative control) were used. (E) dAP-7 cells were similarly treated as in panel D and
analyzed for cell death (apoptosis) by measuring DNA fragmentation at 405-nm absorbance in cell lysates. The error bars indicate standard deviations.
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macrophages and T cells and infected astrocytes and microglia,
have been linked to neurotoxicity (122). Thus, we were interested
in assaying the cytokine contents of these supernatants. To this
end, circulating exosomes were isolated by ExoQuick precipita-
tion. Exoquick-purified exosomes have been previously shown to
contain RNA and protein of higher purity and in greater quantity
than other routinely used isolation methods (123). RayBio cyto-
kine arrays were used to screen 23 immunoregulatory molecules
in pooled supernatants from infected primary macrophages sub-
jected to 18BIOder treatment. Cytokine detection revealed
changes between untreated infected and treated cells (Fig. 7C).
There was a decrease in the majority of molecules screened, in-
cluding granulocyte colony-stimulating factor (G-CSF) and gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF); GRO
and GRO-; IL-1, -2, -3, -5, -6, -7, -8, -10, -13, and -15; gamma
interferon (IFN-); monocyte chemoattractant protein 1
(MCP-1) and -2; MIG; RANTES; transforming growth factor 1
(TGF-1); and tumor necrosis factor alpha (TNF-). However,
MCP-3 and TNF- levels were not changed compared to the
DMSO control. Of interest, MCP-3 is a CCR5 antagonist and, as
such, could provide endogenous protection by inhibiting HIV-1
entry (124).
Consequently, we were interested in determining whether
18BIOder would also display comparable cytoprotection of neu-
ronal cultures from HIV-1 Tat-induced cell death (125). dAP-7
cells were preincubated with 18- or 6BIOder (0.1 M) for 1 h prior
to exposure to the Tat protein. Both cell viability and cell death
(apoptosis) were analyzed 18 h following Tat exposure by CellTiter-
Glo and DNA fragmentation measurement assays, respectively.
The results in Fig. 7D showed that treatment with functionally
active full-length Tat protein (Tat1-86) significantly reduced cell
viability compared to negative-control BSA treatment using the
Student t test (P  0.02). Transcriptionally nonfunctional Tat
peptide, which contains the basic domain and has been shown to
be neurotoxic (32), served as a positive control. Of importance,
18BIOder was protective against Tat-mediated cell death. Inter-
estingly 18BIOder also showed marked, although not statistically
significant, reduction of apoptosis caused by Tat1-86 treatment
when DNA fragmentation was measured (Fig. 7E). Collectively,
these results indicate that 18BIOder may be able to confer cyto-
protection from Tat-induced cell death on neuronal cultures.
DISCUSSION
In the current study, we focused on defining unique cellular tar-
gets that may be used to inhibit HIV-1, decrease viral transcription
at a low 50% inhibitory concentration (IC50), and avoid interfer-
ence with native cellular transcription. We have expanded the
characterization of potent HIV-1 Tat-dependent transcription in-
hibitors derived from a screen of over 3,000 compounds that ini-
tially identified the parental 6BIO compound (33) as a potent
inhibitor of GSK-3 (126).
Originally described as a key regulatory enzyme in the process
of glycogen synthesis, mammalian GSK-3 is a serine/threonine
kinase that harbors two highly homologous isoforms, GSK-3
and GSK-3 (127). GSK-3 is a constitutively active endogenous
enzyme that has a variety of multifaceted roles in cellular signaling
that include regulation of neuronal plasticity, gene expression,
and cell survival. GSK-3 is currently believed to be a key compo-
nent of certain neurodegenerative and psychiatric diseases (111).
Identification of GSK-3 inhibition by lithium at an IC50 of ap-
proximately 2 mM (128) provided an extraordinarily valuable
tool that expanded the repertoire of inhibitors, along with SB-
216763 (IC50, 34 nM) and SB-415286 (IC50, 78 nM) (129). The
parental compound in this study, 6BIO, is a synthetic compound
derived from its natural 6-bromoindirubin product, which dis-
plays a low IC50 of 5 nM and specific inhibition of GSK-3 both in
vitro and in vivo in Xenopus embryos (126). Further characterized
by the same group via cocrystallization experiments, 6BIO was
demonstrated to bind the ATP pocket of GSK-3. In addition,
6BIO has been shown to inhibit the cyclin-dependent kinase com-
plexes Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p35 at higher
IC50s of 0.32, 0.30, and 0.08 M, respectively (126). Also, the
previously characterized 6BIO derivative 6BIOder has been
shown to exert specific GSK-3 inhibition and to confer neuronal
protection with decreased cytotoxicity compared to the parental
6BIO compound (33). Of interest, 6BIOder also exhibited potent
viral suppression and cytoprotection in neurodegenerative infec-
tion by VEEV (95). 6BIOder was shown to decrease VEEV-in-
duced cell death and replication at an IC50 of approximately
0.5 M.
Our studies demonstrate the ability of a 6BIO derivative,
18BIOder, to inhibit Tat-dependent transcription. This small-
molecule inhibitor has a low IC50 in transcriptional inhibitory
assays and is composed of half the structure of 6BIO, making it an
easier and more cost-effective compound to synthesize (Fig. 1A
and B). To better define the mechanistic structure of these inhib-
itors, we docked these compounds to GSK-3 to probe their bind-
ing modes using a known crystal structure of the GSK-3 complex
with a related small-molecule ligand, 6BIO (PDB ID 1UV5). We
verified the accuracy of our docking simulations by closely repro-
ducing the experimentally known binding mode of 6BIO (data
not shown). Indeed, a very small root mean square deviation
(RMSD) of 0.79 Å between the simulated and experimental bind-
ing conformations of 6BIO was obtained. The binding modes of
the other three BIOder compounds, based on our docking simu-
lations, were very distinct from each other.
From our simulation results, 6BIO and 6BIOder presented
rather similar binding modes, forming hydrogen bonds with res-
idues D133 and V135 (data not shown). Hydrogen bonding with
the backbone portion of these two key residues, D133 and V135,
was also observed among many other GSK-3 inhibitors (130,
131). Gentile et al. (130), using affinity-based screening of large-
scale DNA-encoded chemical libraries, were able to select GSK-3
inhibitors of the desired specificity that formed one additional,
albeit weak, hydrogen bond with the side chain of K85. While it
remains unknown why interactions with K85 might enhance spec-
ificity, K85 could play a very important role, since it is well known
that its equivalent, K33, in CDK2 with a flexible side chain was able
to form salt bridges with the phosphate groups of ATP upon cyclin
binding to activate CDK2 (132, 133). It is thus interesting to note
that 18BIOder formed a very strong hydrogen bond with K85
(data not shown). However, 18BIOder could no longer maintain
hydrogen bonding with D133 and V135 like 6BIO/6BIOder. It
remains to be seen if it is desirable to design a BIOder that merges
6BIOder and 18BIOder to form strong hydrogen bonds with all
three residues, D133, V135, and K85. Finally, 19BIOder moved to
a surprisingly different location in its binding mode to GSK-3
from that used by 6BIOder and 18BIOder.
Similar to its potent inhibitory parent compound, 6BIOder,
18BIOder demonstrates its ability to inhibit Tat-dependent
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HIV-1 transcription without inducing significant cellular toxicity
(Fig. 2). 18BIOder was also found to significantly inhibit viral
replication in chronically infected T cells and PBMCs (Fig. 3A and
C, respectively). Previously, it was shown that 6BIOder can po-
tently inhibit viral replication in infected PBMCs at lower concen-
trations, though this small-molecule inhibitor was not tested in
chronically infected high-viral-load-producing cells, as was done
in this study (33). Interestingly, we have observed different levels
of GSK-3 in the fractions containing lower-molecular-weight
complexes present only in infected T cells or monocytoid cells
(Fig. 5A and B, compare lanes 8 through 11), showing that protein
levels or availability of GSK-3 present in these lower-molecular-
weight fractions may play a role in the 18BIOder mechanism of
inhibition.
Here, we also describe the general expression signature of
GSK-3 in HIV-1 infection (Fig. 4A to C and 5A to E). We found
that endogenous GSK-3 is overexpressed during infection in a
variety of cells, including T cells, monocytes, and PMA-treated
monocytoid cells. Furthermore, though modest, we have identi-
fied a slightly increased redistribution of cytoplasmic GSK-3 in
cells that have undergone viral activation, suggesting that GSK-3
may be modulating signal transduction pathways in a way that
benefits viral mechanisms of survival and infectivity. GSK-3 is
characterized by regulation of transcription factors and cofactors
that include -catenin, c-Jun, c-Myc, C/EBP/, NFATc, RelA,
and CREB (134, 135). Moreover, most of these regulatory targets
have been implicated in Tat-mediated transcription (136). Mem-
bers of the lymphoid enhancer factor-1/T-cell factor (LEF-1/TCF)
family of transcription factors interact with -catenin and play a
role as nuclear effectors of Wnt signaling, which includes gene
targets that impact cell differentiation, communication, apoptosis
and survival, and proliferation (137, 138). A possibility of in-
creased cytoplasmic GSK-3 in the presence of activated HIV-1
involves the -catenin signaling pathway, which has been shown
to function as an intrinsic molecular pathway restricting HIV-1
replication in PBMCs (137). GSK-3 forms part of a repressive
multiprotein cytoplasmic complex, in addition to adenomatous
polyposis coli (APC) and axin proteins, which target -catenin for
degradation. The TCF-4/-catenin interaction is linked to HIV-1
replication inhibition in multiple cell types, including astrocytes
and lymphocytes. Recently, TCF-4 and -catenin have been
shown to have multiple binding sites relative to the transcriptional
initiation site at the 5=HIV-1 LTR (139). In particular, TCF-4 and
-catenin at position 143 associate with the nuclear matrix
binding protein SMAR1, which may tether the HIV-1 DNA seg-
ment into the nuclear matrix and away from transcriptional ma-
chinery, resulting in repression of basal HIV-1 LTR transcription.
Thus, increased cytoplasmic GSK-3 may be acting as a transcrip-
tional activating complex by repressing the -catenin HIV-1 re-
strictive signaling pathway.
HIV-1 selectively targets the basal ganglion region of the brain,
which results in loss of dopaminergic and nigrostriatal neurons
(140, 141). Overexpression of exogenous GSK-3 in neurons im-
pairs neurite growth (142), and this impairment can be overcome
when neurons overexpressing exogenous active enzyme are
treated with lithium. Likewise, Tat has been shown to induce
GSK-3 activity, which can be abrogated by lithium treatment
(143). 18BIOder is able to confer neuronal protection with less
toxicity than 6BIO and exhibits potent inhibition of HIV-1 Tat-
dependent transcription. In addition to viral transcriptional inhi-
bition and thus decrease in Tat production and release, 18BIOder
confers microglial and neuronal cytoprotection (Fig. 7). Although
the mechanism of neuroprotection is not known, modulation of
the GSK-3 signaling pathways and GSK-3-mediated transcrip-
tional regulation of neurotrophic growth factors may play an im-
portant role. The complete role of GSK-3 in HAND remains
unclear; however, its actions have been well characterized in var-
ious prevailing diseases, such as neurocognitive and mood disor-
ders, Alzheimer’s disease, diabetes, and cancer (144). Recently,
GSK-3 has been found to play a vital role in the inflammation
process, providing a common link between the enzyme and the
various diseases it influences, possibly including HAND (145).
Given that indirect neurodegeneration in HAND involves soluble
factors released by macrophages and microglia as part of the host
inflammatory response to HIV-1 infection (some of which have
been shown to act as nonviral neurotoxins), GSK-3-mediated
modulation of the inflammatory response may add a layer of com-
plexity to its role in HAND (146–148).
Currently, the possibility that these compounds exert their in-
hibitory function through other, unidentified single or collective
kinases, which would result in synergistic HIV-1 transcriptional
inhibition, cannot be ruled out. However, we have presented
novel data indicating the exclusive presence of new GSK-3 com-
plexes in infected cells (Fig. 5A to E) and that they are more sus-
ceptible to 18BIOder kinase inhibition without altering normal
cellular transcription (Fig. 6A to C). In uninfected cells, GSK-3
was present in a complex with a molecular mass of 300 kDa,
which is likely to be composed of either homo- or heterodimers of
GSK-3 in conjunction with possible chaperone proteins or other
bound proteins. However, HIV-1-infected cells displayed an ex-
tended set of lower-molecular-weight complexes in addition to
the dominant 300-kDa complex. We hypothesize that the larger
complex is formed by multimers of GSK-3 and possibly un-
known proteins, while the smaller complexes may be constituted
of monomers only. These elution profiles of GSK-3 are novel and
reveal a redistribution of GSK-3 during infection that is not ob-
served in uninfected cells. Interestingly, this elution profile was
confirmed in two chronically HIV-1-infected cell line models.
Relevant to this study, size fractionation of mock- and VEEV-
infected cells revealed a similar distribution of GSK-3 during
infection (95). Though only speculative at this point, it is possible
that infection alters cytoplasmic complexes that are normally
masking the bipartite nuclear localization signal (NLS) present in
GSK-3, which spans residues 85 to 103 (103). Inhibitory cyto-
plasmic complexes may allow protein localization regulation pre-
dominantly in the cytoplasm while permitting nuclear accumula-
tion in response to demand, in this case viral infection. The NLS
was found to be both sufficient and required for nuclear localiza-
tion. Current proteomics experiments from lower fraction ex-
tracts from HIV-1-infected versus VEEV-infected cells may un-
cover stoichiometry of GSK-3 and its possible partners, defining
the mechanism of 18BIOder inhibition in HIV-1-infected cells.
This may also explain the inherent specificity of 18BIOder for
HIV-1 transcription (nuclear event) versus 19BIOder inhibition
of VEEV transcription (cytoplasmic event).
Lastly, we have demonstrated the efficacy of 18BIOder in
HIV-1 replication inhibition in vivo (data not shown). Treatment
with both 1.0 mg/kg and 10 mg/kg of 18BIOder resulted in viral
suppression, as measured through reverse transcriptase activity
from treated animals. Longitudinal measurements over a span of
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29 days showed effective viral suppression at 1.0 mg/kg 18BIOder
shortly after treatment. When left untreated, the virus would re-
sume replication, a response comparable to that of cART, which
requires daily dosage for effective plasma control of the viral load.
Of interest, we observed effective inhibition after treatment inter-
ruption. This is significant, since it reinforces the notion that gen-
erating host-based therapies may offer new opportunities to over-
come viral adaptation and resistance to virus-based inhibitors. A
possible in vivo model is depicted in Fig. 8, where HIV-1 neuro-
toxicity may be derived from cytokines and soluble viral proteins,
gp120 and Tat, released from infected astrocytes and microglia
and 18BIOder may exert its effects by altering these neurotoxin
releases.
Future studies will focus more on identification of candidate
factors that could regulate both LTR and the host. Using reverse-
phase protein microarray (RPMA) technology, we have deter-
mined in preliminary experiments that GSK-3 affects protein
nodes that control apoptosis and survival, especially in 18BIOder-
treated cells. Validation of these nodes will require future studies
in primary cells.
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